Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 11Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Bites and Stings 1

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × AMG 757 × Clear all
NCT06064500 2025-03-10

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Amgen

Approved for marketing
Thoracic

Bites and Stings, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡